Blog

April 4, 2024 – The Society for Clinical Research Sites (SCRS) is pleased to welcome Translational Drug Development (TD2) as an SCRS Global Impact Partner and Oncology Spirit Partner. TD2 is a leading provider of comprehensive preclinical drug development, translational and clinical trial services based in Scottsdale, Arizona. SCRS Global Impact Partners (GIPs) are comprised...

Read more +

SCOTTSDALE, ARIZONA, UNITED STATES, April 3, 2024 /EINPresswire.com/ — Translational Drug Development (TD2), a precision oncology contract...

Read more +

SCOTTSDALE, ARIZONA, USA, February 1, 2024 /EINPresswire.com/ — Translational Drug Development (TD2), a leading provider of comprehensive...

Read more +

SCOTTSDALE, ARIZONA, USA, December 5, 2023 /EINPresswire.com/ Translational Drug Development (TD2), a precision oncology contract research...

Read more +

CARLSBAD, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on...

Read more +

View More
Skip to content